N-(2-pyrrolidin-1-ylethyl)benzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(2-pyrrolidin-1-ylethyl)benzamide
• 化学式: C₁₃H₁₈N₂O
• mdl: MFCD01830874
• 分子量: 218.29
• InChiKey: ZTISWCXLXLMLLY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.461
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] UREA DERIVATIVES USEFUL AS KINASE INHIBITORS<br/>[FR] DÉRIVÉS D'URÉE UTILES COMME INHIBITEURS DE KINASE
  申请人：RESPIVERT LTD

  公开号：WO2015092423A1

  公开（公告）日：2015-06-25

  There are provided compounds of formula I, wherein R1, R1A, R1C to R1E, Ra, Rb, X1, E and G have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.

  提供了化合物I的结构，其中R1、R1A、R1C至R1E、Ra、Rb、X1、E和G的含义如描述中所示，这些化合物具有抗炎活性（例如通过抑制p38丝裂原活化蛋白激酶家族中的一个或多个成员；Syk激酶；以及酪氨酸激酶Src家族的成员之一），并且在治疗中有用，包括在制药组合物中，特别是用于治疗炎症性疾病，包括肺部、眼睛和肠道的炎症性疾病。
• COMPOSITIONS AND METHODS FOR TREATING ALCOHOL USE DISORDERS, PAIN AND OTHER DISEASES
  申请人：Wu Jay Jie-Qiang

  公开号：US20110301149A1

  公开（公告）日：2011-12-08

  The present invention provides compounds which antagonize epsilon protein kinase C (PKCε). These compounds have a structural formula (Ia), (Ic) or (II). The present invention also provides pharmaceutical compositions containing these compounds and methods of treating various diseases, conditions, and/or symptoms by using these compounds.

  本发明提供了对抗ε蛋白激酶C（PKCε）的化合物。这些化合物具有结构式（Ia）、（Ic）或（II）。本发明还提供了包含这些化合物的药物组合物，并使用这些化合物治疗各种疾病、病症和/或症状的方法。
• NOVEL MCH RECEPTOR ANTAGONISTS
  申请人：Arnold Macklin Brian

  公开号：US20120302547A1

  公开（公告）日：2012-11-29

  The present invention relates to a melanin concentrating hormone antagonist compound of formula (I) wherein R 1 , R a , R b , R 2 , L 1 , R 3 , R 4 and R 5 are as defined, or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture of diasteromers thereof useful in the treatment, obesity and related diseases.

  本发明涉及一种公式（I）的黑色素浓集激素拮抗剂化合物，其中R1、Ra、Rb、R2、L1、R3、R4和R5如定义所述，或其药学上可接受的盐、对映体、非对映异构体或二异构体混合物，用于治疗肥胖和相关疾病。
• SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS
  申请人：ALLERGAN, INC.

  公开号：US20130190338A1

  公开（公告）日：2013-07-25

  The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.

  本发明涉及新型硫衍生物，其制备方法，含有它们的药物组合物以及它们作为药物化学因子受体调节剂的用途。
• IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE
  申请人：BI Yingzhi

  公开号：US20130245021A1

  公开（公告）日：2013-09-19

  Imidazo[1,2-b]pyridazine-based compounds of the formula: are disclosed, wherein R 1 , R 2 and R 3 are defined herein. Compositions comprising the compounds and methods of their use to treat, manage and/or prevent diseases and disorders mediated by mediated by adaptor associated kinase 1 activity are also disclosed.

  本发明揭示了基于咪唑并[1,2-b]吡啶的化合物，其化学式如下：其中R1、R2和R3在此定义。本发明还揭示了包含这些化合物的组合物以及它们的使用方法，用于治疗、管理和/或预防由适配器相关激酶1活性介导的疾病和障碍。